166
pts
FDA declines to review Moderna's mRNA flu shot
AI Summary
The FDA has decided not to review Moderna's mRNA flu vaccine, delaying its potential introduction to the market. This decision comes as health officials evaluate the effectiveness and safety of the new vaccine amid ongoing discussions regarding mRNA technology in flu prevention.